Latest News and Press Releases

Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag solgt 2 000 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS ingen aksjer i PCI Biotech Holding...

Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag kjøpt 240 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS 2 000 000 aksjer, noe som utgjør 5,36%...

Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector...

Oslo, 22 May 2025. The Annual General Meeting in PCI Biotech Holding ASA took place today, 22 May 2025.  All the matters on the agenda were approved and the minutes of the Annual General Meeting are...

Oslo, 20 May 2025. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI...

Oslo, Norway, 30 April 2025 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park on 22 May 2025 at 10:00am (CEST). The...

Oslo, Norway, April 24, 2025The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2024. Please find the report attached, as well as the report according to the European...

Oslo (Norway), 27 February 2025 – PCI Biotech (OSE: PCIB), today announces its preliminary full year 2024 results. Please find enclosed the interim report and presentation. Highlights review ...

Oslo, Norway, 25 February 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's full-year 2024 interim report on Thursday 27 February 2025, 08:30am – 09:00am CET (local...

Oslo, 10 January 2025 - PCI Biotech (OSE: PCIB), today announced that the Board of Directors has granted share options to Morten Luhr who has been promoted to Chief Scientific Officer (CSO) from...